Health Care · Health Care Equipment · US stock · price as of 16 Oct 2026
Key indicators
Price
$141.10
52-week range
$126.40 – $354.88
Market cap
$9.8B
P/E (trailing)
26.5×
EV / EBITDA
16.6×
Free-cash-flow yield
3.0%
Dividend yield
–
Revenue (last 12 months)
$3.1B
Revenue growth (3y a year)
27.5%
Operating margin
16.9%
Return on invested capital
21.3%
Net debt / EBITDA
0.7×
Fair value
Blended fair value$168.91 range $109 – $160
Versus priceFair+20% to fair value
Peer multiples
$89.39
Fundamentals-adjusted multiple
$129.27
10-year DCF (market-scaled)
$288.07
Earnings power value (floor, not blended)
$40.58
Model uncertainty
High
X-Ray Score
69/ 100 · High confidence · ahead of 93% of sector peers
Valuation58
Growth91
Profitability64
Financial health67
Dividends–
Five-year price chart navy: price · brown: 200-day average · blue band: fair value range
Executive summary
Insulet develops and sells the Omnipod, a small wearable insulin delivery device that people with diabetes attach to the body instead of using injections or a tubed pump. Revenue comes mainly from recurring sales of disposable pods, which are replaced regularly, along with the companion controller software. Products reach patients through pharmacies, distributors and healthcare providers, with reimbursement from insurers playing a central role in the business.
Revenue of $3.1 billion was recorded for the latest twelve months; sales grew 27.5% a year over the past three years. Insulet Corp converts that into an operating margin of 16.9%. Return on invested capital comes to 21%. Net debt to EBITDA is 0.7 times.
StocksXray gives Insulet Corp an X-Ray Score of 69 out of 100 (high confidence), ahead of 93% of the S&P 500 stocks in its sector. Its strongest lens is growth (91) and its weakest is valuation (58).
Our fair value blend is $168.91 (range $109.33 to $160.26). At $141.10 the stock trades 16% below that blend, so the label is "Fair" with high model uncertainty. Fair value is a range, not a price target.
XStocksXray
Insulet Corp (PODD)
Valuation history multiples at each fiscal year-end price; the last column uses today's price and the last twelve months
FY2021
FY2022
FY2023
FY2024
FY2025
Now
Price
$266.07
$294.39
$216.98
$261.07
$284.24
$141.10
Market cap
$18.2B
$20.6B
$16.0B
$19.3B
$20.4B
$9.8B
P/E
1,108.6×
4,205.6×
73.8×
45.2×
81.7×
26.5×
EV / revenue
17.0×
16.3×
9.8×
9.5×
7.6×
3.3×
EV / EBITDA
102.0×
211.2×
57.0×
50.6×
36.6×
16.6×
Price / free cash flow
–
–
227.9×
63.2×
54.1×
33.3×
Free-cash-flow yield
−1.0%
−0.0%
0.4%
1.6%
1.8%
3.0%
Price / book
32.8×
43.2×
21.8×
15.9×
13.5×
6.9×
Dividend yield
–
–
–
–
–
–
Fundamentals checklist ● 10 Good · ● 4 Average · ● 1 Bad · each check graded against the sector
Cash quality
Earnings backed by cash−4.3%Average
Free-cash-flow yield3.0%Bad
Risk models
Altman Z score4.7×Good
Piotroski F-Score7 of 9Average
Growth
EPS growth (3y)267.7%Good
Revenue growth (3y)27.5%Good
Growth consistency100%Good
Balance sheet
Current ratio2.5×Good
Net debt / EBITDA0.7×Good
Interest cover8.8×Average
Valuation
Fair value vs price1.2×Good
EBIT / EV yield5.1%Good
Profitability
Return on invested capital21.3%Good
Operating margin16.9%Average
Gross profitability68.6%Good
XStocksXray
Insulet Corp (PODD)
Financials US$ millions, from SEC filings; last column is the last twelve months
Income statement
FY21
FY22
FY23
FY24
FY25
LTM
Revenue
1,099
1,305
1,697
2,072
2,708
3,054
Gross profit
752
806
1,160
1,446
1,940
2,170
Operating income
126
38
220
309
474
516
Net income
17
5
206
418
247
375
Diluted EPS ($)
0.24
0.07
2.94
5.78
3.48
5.32
Free cash flow
-180
-4
70
305
378
294
Gross margin
68.4%
61.7%
68.3%
69.8%
71.6%
71.1%
Operating margin
11.5%
2.9%
13.0%
14.9%
17.5%
16.9%
Net margin
1.5%
0.4%
12.2%
20.2%
9.1%
12.3%
Balance sheet
FY21
FY22
FY23
FY24
FY25
LTM
Total assets
2,049
2,251
2,588
3,088
3,190
3,165
Cash
806
690
704
953
716
535
Total debt
1,274
1,402
1,416
1,380
949
948
Equity
556
476
733
1,212
1,515
1,422
Dividend per share ($)
–
–
–
–
–
–
Revenue and net income US$ billions: navy revenue, teal net income
Every number comes from SEC filings, end-of-day prices and the StocksXray models described on the methodology page. The X-Ray Score ranks each metric against the company's own sector. Fair value blends three models and carries a typical error of about 40%, so treat it as a range. Analyst ratings, price targets and earnings-call summaries are not part of this report. Educational research, not financial advice; read the disclaimer.